Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. (Ventrus) is a privately held growing specialty pharmaceutical company. It is principally engaged in the development and commercialization of gastrointestinal (GI) products. It mainly focuses on licensing late-stage GI products in the areas of unmet need. Currently, the company has licensed three late-stage GI product candidates, namely, VEN 307, a diltiazem cream for pain relief associated with anal fissure; VEN 308, a Phenylephrine gel to treat feacal incontinence associated with ileal pouch anal anastomosis; and VEN 309, a Iferanserin ointment for the treatment of hemorrhoids. The company has signed an exclusive license agreement with Sam Amer & Company (Amer) to develop novel topical treatment for Hemorrhoids. Ventrus is headquartered at Greenwood Village in Colorado, the US.